Please login to the form below

Not currently logged in
Email:
Password:

Stivarga

This page shows the latest Stivarga news and features for those working in and with pharma, biotech and healthcare.

Chi-Med goes for third IPO in Hong Kong

Chi-Med goes for third IPO in Hong Kong

It was the second VEGF inhibitor to reach the Chinese market, after Bayer’s Stivarga, and Chi-Med is partnering with Eli Lilly to commercialise the drug across China whilst also

Latest news

More from news
Approximately 12 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga.

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics